Company profile

Ronald Cohen
Fiscal year end

ACOR stock data

FINRA relative short interest over last month (20 trading days) ?


7 Nov 19
19 Feb 20
31 Dec 20


Company financial data Financial data

Quarter (USD) Sep 19 Jun 19 Mar 19 Dec 18
Revenue 47.72M 50.05M 44.14M 69.15M
Net income -263.54M -27.49M -47.61M 9.6M
Diluted EPS -5.55 -0.58 -1 0.2
Net profit margin -552% -54.91% -108% 13.88%
Operating income -259.35M -23.39M -43.38M -49.3M
Net change in cash -28.13M -49.45M -96.47M -27.45M
Cash on hand 119.52M 147.65M 197.09M 293.56M
Cost of revenue 7.99M 9.4M 8.8M 23.15M
Annual (USD) Dec 18 Dec 17 Dec 16 Dec 15
Revenue 471.43M 588.29M 519.6M 492.66M
Net income 33.68M -223.36M -34.62M 11.06M
Diluted EPS 0.71 -4.86 -0.76 0.25
Net profit margin 7.14% -37.97% -6.66% 2.24%
Operating income 38.49M -232.81M -35.98M 33.99M
Net change in cash -13.5M 148.53M 5.33M -28.97M
Cash on hand 293.56M 307.07M 158.54M 153.2M
Cost of revenue 99.31M 135.08M 107.48M 92.3M

Financial data from company earnings reports

13F holders
Current Prev Q Change
Total holders 157 166 -5.4%
Opened positions 20 17 +17.6%
Closed positions 29 39 -25.6%
Increased positions 58 79 -26.6%
Reduced positions 43 40 +7.5%
13F shares
Current Prev Q Change
Total value 155.92M 451.03M -65.4%
Total shares 54.26M 58M -6.4%
Total puts 365.82K 143.14K +155.6%
Total calls 263.99K 225.72K +17.0%
Total put/call ratio 1.4 0.6 +118.5%
Largest owners
Shares Value Change
BLK BlackRock 7.83M $22.49M +11.8%
FMR 7.13M $20.46M +0.2%
Vanguard 5.98M $17.15M -3.5%
Renaissance Technologies 4.06M $11.64M -11.0%
Dimensional Fund Advisors 3.15M $9.04M -7.0%
Scopia Capital Management 2.77M $7.96M -16.5%
Baker Bros. Advisors 2.23M $6.41M +11.0%
Partner Fund Management 2.19M $6.28M NEW
Acadian Asset Management 1.46M $4.21M +29.1%
STT State Street 1.41M $4.06M -63.3%
Largest transactions
Shares Bought/sold Change
STT State Street 1.41M -2.44M -63.3%
Partner Fund Management 2.19M +2.19M NEW
Perceptive Advisors 0 -1.13M EXIT
BLK BlackRock 7.83M +827.85K +11.8%
PRU Prudential Financial 228.16K -642.17K -73.8%
Point72 Asset Management 1.01M +593.66K +142.9%
Scopia Capital Management 2.77M -549.68K -16.5%
Renaissance Technologies 4.06M -501.6K -11.0%
DB Deutsche Bank 158.88K -495.67K -75.7%
Aqr Capital Management 676.84K +439.92K +185.7%

Financial report summary

Management Discussion
  • We recognize product sales of Inbrija following receipt of product by companies in our distribution network, which primarily includes specialty pharmacy providers and ASD Specialty Healthcare, Inc. We recognized net revenue from the sale of Inbrija of $4.9 million for the three-month period ended September 30, 2019.
  • We recognize product sales of Ampyra following receipt of product by companies in our distribution network, which primarily includes specialty pharmacy providers. We recognized net revenue from the sale of Ampyra of $37.6 million and $137.8 million for the three-month periods ended September 30, 2019 and 2018, respectively, a decrease of $100.2 million, or 73%. The net revenue decrease comprised decreased net volume of $100.3 million partially offset by discount and allowance adjustments of $0.1 million.
  • Discounts and allowances which are included as an offset in net revenue consist of allowances for customer credits, including estimated chargebacks, rebates, returns and discounts. Discounts and allowances are recorded following shipment of our products to our customers. Adjustments are recorded for estimated chargebacks, rebates, and discounts. Discounts and allowances also consist of discounts provided to Medicare beneficiaries whose prescription drug costs cause them to be subject to the Medicare Part D coverage gap (i.e., the “donut hole”). Payment of coverage gap discounts is required under the Affordable Care Act, the health care reform legislation enacted in 2010. Discounts and allowances may increase as a percentage of sales as we enter into managed care contracts in the future.
Content analysis ?
H.S. sophomore Avg
New words: adult, advisor, alpha, compensatory, David, delisted, Employment, episodic, hard, Jane, Lawrence, negative, negotiated, opportunistically, permanent, plant, premium, suitability, Technical, top, warrant, Wasman
Removed: abnormal, academic, Academy, accelerate, administering, advanced, affiliate, affiliated, Agency, Alkem, AmerisourceBergen, analyzed, ANDA, Apotex, Ascend, asserted, asserting, Aurobindo, blood, Bureau, candidate, center, challenged, chemistry, CHMP, Committee, conducted, consistent, convenient, Defense, define, demyelinating, distribute, earlier, elevation, EMA, expiration, FL, hepatoxicity, Human, imaging, import, Importantly, increased, infringe, infringement, injunctive, intact, integrated, judicial, launching, lesion, magnetization, manifested, Medicinal, meeting, Micro, myelin, myelination, Mylan, notification, obtaining, Overview, Paragraph, Pharma, pharmaceutical, population, ratio, relapse, removed, repair, requested, resolved, routed, Roxane, stopped, stopping, submission, Sun, Teva, therapy, timed, transfer, transplant, triptan, USA, VA, valid, validity, vigorously, walk, zolmitriptan


Compositions and Methods for the Treatment of CNS Injuries
16 Jan 20
The present invention is directed to a method of improving functional recovery following a central nervous system contusion injury.
Therapeutic Dosing of a Neuregulin or a Subsequence Thereof for Treatment or Prophylaxis of Heart Failure
9 Jan 20
The invention relates to treatment of heart failure in a mammal.
Water-soluble Acetaminophen Analogs
2 Jan 20
The present invention provides water-soluble acetaminophen prodrugs and formulations which may be suitable for parenteral administration.
Methods for Treating an Impairment In Gait And/or Balance In Patients with Multiple Sclerosis Using an Aminopyridine
19 Dec 19
Disclosed herein is use of one or more aminopyridines in methods and compositions for treatment of impairments in gait or balance in patients with multiple sclerosis.
Methods of Using Sustained Release Aminopyridine Compositions
17 Oct 19
A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at about 12 hours and the use of the composition to treat various neurological diseases, including multiple sclerosis.